The Efficacy and Safety of ALIC/NAcc-DBS for Treatment-refractory OCD
NCT: NCT04967560 · COMPLETED
Brief Summary
The present study aims to explore the efficacy and safety of DBS targeted the combination of the anterior limb of internal capsule and nucleus accumbens (ALIC/NAcc-DBS) to refractory OCD, based on multicenter, randomized, double-blinded, sham-stimulation controlled design, that could help to obtain stronger evidence of the efficacy of multiple targets.
Frequently Asked Questions
What is The Efficacy and Safety of ALIC/NAcc-DBS for Treatment-refractory OCD?
The Efficacy and Safety of ALIC/NAcc-DBS for Treatment-refractory OCD is a clinical trial registered under NCT04967560. Current status: COMPLETED.
What is the status of NCT04967560?
The current status of NCT04967560 (The Efficacy and Safety of ALIC/NAcc-DBS for Treatment-refractory OCD) is: COMPLETED.
When did The Efficacy and Safety of ALIC/NAcc-DBS for Treatment-refractory OCD start?
The Efficacy and Safety of ALIC/NAcc-DBS for Treatment-refractory OCD started on 2021-07-30.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.